Charles River Laboratories International, Inc. CRL

Revenue Intelligence Report • 60 quarters of SEC filing data • Updated 2026-03-15

Charles River Laboratories International, Inc. has a forecasted full-year revenue of $4.1B, a +2.1% year-over-year change, based on 60 quarters of SEC filing data. Key revenue drivers include SG&A ($4.89 per $1). The ARDL model achieves strong accuracy at 3.1% MAPE.

Investment Thesis

The econometric model achieves strong accuracy (3.1% MAPE), suggesting Charles River Laboratories International, Inc.'s revenue trajectory is well-characterized by its spending patterns. Each $1 of SG&A spending generates $4.89 in revenue, reflecting strong commercial efficiency.

Next FY Revenue
$4.10B
+2.1% YoY
SG&A Multiplier
$4.89 per $1
Model Accuracy
3.1% MAPE
Holdout validation: The model predicted $1.0B vs the actual $1.0B — an error of 2.7%.
Note: Charles River Laboratories International, Inc. does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

CRL Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.0B $1.0B $1.0B – $1.1B +1.8% ✓ In range
Q1 2026 $1.0B $0.9B – $1.1B +3.5%
Q2 2026 $1.0B $0.9B – $1.1B -0.4%
Q3 2026 $1.0B $0.9B – $1.1B +2.0%
Q4 2026 $1.0B $0.9B – $1.1B +3.4%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Charles River Laboratories International, Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.9878 -1.2% In line with trend 16
FQ2 (Dec–Feb) 1.0183 +1.8% In line with trend 10
FQ3 (Mar–May) 0.979 -2.1% In line with trend 15
FQ4 (Jun–Aug) 1.027 +2.7% In line with trend 15

How Spending Drives Revenue

CRL Spending Timing
Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (linear) with 60 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

ABBV SYK JNJ BDX A UNH COO CAH